Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of drugs used to treat human immunodeficiency virus (HIV) infection. NRTIs are metabolized into active nucleotide triphosphate derivatives in the body and bind competitively to the HIV reverse transcriptase, preventing the conversion of viral RNA into DNA, thereby inhibiting viral replication.
The global Nucleoside Reverse Transcriptase Inhibitors market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淣ucleoside Reverse Transcriptase Inhibitors Industry Forecast鈥� looks at past sales and reviews total world Nucleoside Reverse Transcriptase Inhibitors sales in 2023, providing a comprehensive analysis by region and market sector of projected Nucleoside Reverse Transcriptase Inhibitors sales for 2024 through 2030. With Nucleoside Reverse Transcriptase Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleoside Reverse Transcriptase Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Nucleoside Reverse Transcriptase Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleoside Reverse Transcriptase Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Nucleoside Reverse Transcriptase Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleoside Reverse Transcriptase Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleoside Reverse Transcriptase Inhibitors.
United States market for Nucleoside Reverse Transcriptase Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Nucleoside Reverse Transcriptase Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Nucleoside Reverse Transcriptase Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Nucleoside Reverse Transcriptase Inhibitors players cover GSK, MSD, Mylan Laboratories, Takeda Pharmaceutical, Emcure Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleoside Reverse Transcriptase Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Tablet
Oral Solution
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GSK
MSD
Mylan Laboratories
Takeda Pharmaceutical
Emcure Pharmaceuticals
LUPIN PHARMS
Aurobindo Pharma
Gilead Sciences
Kainos Medicine
Celltrion
Strides Pharma
Cipla
Vibe Healthcare
Shionogi
ViiV Healthcare
HETERO LABS
Blanver Farmoquimica
Viriom
Apotex
DESANO
Hansoh Pharma
Genuine Biotech
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nucleoside Reverse Transcriptase Inhibitors market?
What factors are driving Nucleoside Reverse Transcriptase Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nucleoside Reverse Transcriptase Inhibitors market opportunities vary by end market size?
How does Nucleoside Reverse Transcriptase Inhibitors break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nucleoside Reverse Transcriptase Inhibitors Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Nucleoside Reverse Transcriptase Inhibitors by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Nucleoside Reverse Transcriptase Inhibitors by Country/Region, 2019, 2023 & 2030
2.2 Nucleoside Reverse Transcriptase Inhibitors Segment by Type
2.2.1 Tablet
2.2.2 Oral Solution
2.3 Nucleoside Reverse Transcriptase Inhibitors Sales by Type
2.3.1 Global Nucleoside Reverse Transcriptase Inhibitors Sales Market Share by Type (2019-2024)
2.3.2 Global Nucleoside Reverse Transcriptase Inhibitors Revenue and Market Share by Type (2019-2024)
2.3.3 Global Nucleoside Reverse Transcriptase Inhibitors Sale Price by Type (2019-2024)
2.4 Nucleoside Reverse Transcriptase Inhibitors Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Nucleoside Reverse Transcriptase Inhibitors Sales by Application
2.5.1 Global Nucleoside Reverse Transcriptase Inhibitors Sale Market Share by Application (2019-2024)
2.5.2 Global Nucleoside Reverse Transcriptase Inhibitors Revenue and Market Share by Application (2019-2024)
2.5.3 Global Nucleoside Reverse Transcriptase Inhibitors Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Nucleoside Reverse Transcriptase Inhibitors Breakdown Data by Company
3.1.1 Global Nucleoside Reverse Transcriptase Inhibitors Annual Sales by Company (2019-2024)
3.1.2 Global Nucleoside Reverse Transcriptase Inhibitors Sales Market Share by Company (2019-2024)
3.2 Global Nucleoside Reverse Transcriptase Inhibitors Annual Revenue by Company (2019-2024)
3.2.1 Global Nucleoside Reverse Transcriptase Inhibitors Revenue by Company (2019-2024)
3.2.2 Global Nucleoside Reverse Transcriptase Inhibitors Revenue Market Share by Company (2019-2024)
3.3 Global Nucleoside Reverse Transcriptase Inhibitors Sale Price by Company
3.4 Key Manufacturers Nucleoside Reverse Transcriptase Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nucleoside Reverse Transcriptase Inhibitors Product Location Distribution
3.4.2 Players Nucleoside Reverse Transcriptase Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Nucleoside Reverse Transcriptase Inhibitors by Geographic Region
4.1 World Historic Nucleoside Reverse Transcriptase Inhibitors Market Size by Geographic Region (2019-2024)
4.1.1 Global Nucleoside Reverse Transcriptase Inhibitors Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Nucleoside Reverse Transcriptase Inhibitors Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Nucleoside Reverse Transcriptase Inhibitors Market Size by Country/Region (2019-2024)
4.2.1 Global Nucleoside Reverse Transcriptase Inhibitors Annual Sales by Country/Region (2019-2024)
4.2.2 Global Nucleoside Reverse Transcriptase Inhibitors Annual Revenue by Country/Region (2019-2024)
4.3 Americas Nucleoside Reverse Transcriptase Inhibitors Sales Growth
4.4 APAC Nucleoside Reverse Transcriptase Inhibitors Sales Growth
4.5 Europe Nucleoside Reverse Transcriptase Inhibitors Sales Growth
4.6 Middle East & Africa Nucleoside Reverse Transcriptase Inhibitors Sales Growth
5 Americas
5.1 Americas Nucleoside Reverse Transcriptase Inhibitors Sales by Country
5.1.1 Americas Nucleoside Reverse Transcriptase Inhibitors Sales by Country (2019-2024)
5.1.2 Americas Nucleoside Reverse Transcriptase Inhibitors Revenue by Country (2019-2024)
5.2 Americas Nucleoside Reverse Transcriptase Inhibitors Sales by Type (2019-2024)
5.3 Americas Nucleoside Reverse Transcriptase Inhibitors Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nucleoside Reverse Transcriptase Inhibitors Sales by Region
6.1.1 APAC Nucleoside Reverse Transcriptase Inhibitors Sales by Region (2019-2024)
6.1.2 APAC Nucleoside Reverse Transcriptase Inhibitors Revenue by Region (2019-2024)
6.2 APAC Nucleoside Reverse Transcriptase Inhibitors Sales by Type (2019-2024)
6.3 APAC Nucleoside Reverse Transcriptase Inhibitors Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Nucleoside Reverse Transcriptase Inhibitors by Country
7.1.1 Europe Nucleoside Reverse Transcriptase Inhibitors Sales by Country (2019-2024)
7.1.2 Europe Nucleoside Reverse Transcriptase Inhibitors Revenue by Country (2019-2024)
7.2 Europe Nucleoside Reverse Transcriptase Inhibitors Sales by Type (2019-2024)
7.3 Europe Nucleoside Reverse Transcriptase Inhibitors Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nucleoside Reverse Transcriptase Inhibitors by Country
8.1.1 Middle East & Africa Nucleoside Reverse Transcriptase Inhibitors Sales by Country (2019-2024)
8.1.2 Middle East & Africa Nucleoside Reverse Transcriptase Inhibitors Revenue by Country (2019-2024)
8.2 Middle East & Africa Nucleoside Reverse Transcriptase Inhibitors Sales by Type (2019-2024)
8.3 Middle East & Africa Nucleoside Reverse Transcriptase Inhibitors Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nucleoside Reverse Transcriptase Inhibitors
10.3 Manufacturing Process Analysis of Nucleoside Reverse Transcriptase Inhibitors
10.4 Industry Chain Structure of Nucleoside Reverse Transcriptase Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nucleoside Reverse Transcriptase Inhibitors Distributors
11.3 Nucleoside Reverse Transcriptase Inhibitors Customer
12 World Forecast Review for Nucleoside Reverse Transcriptase Inhibitors by Geographic Region
12.1 Global Nucleoside Reverse Transcriptase Inhibitors Market Size Forecast by Region
12.1.1 Global Nucleoside Reverse Transcriptase Inhibitors Forecast by Region (2025-2030)
12.1.2 Global Nucleoside Reverse Transcriptase Inhibitors Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Nucleoside Reverse Transcriptase Inhibitors Forecast by Type (2025-2030)
12.7 Global Nucleoside Reverse Transcriptase Inhibitors Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.1.3 GSK Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 MSD
13.2.1 MSD Company Information
13.2.2 MSD Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.2.3 MSD Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 MSD Main Business Overview
13.2.5 MSD Latest Developments
13.3 Mylan Laboratories
13.3.1 Mylan Laboratories Company Information
13.3.2 Mylan Laboratories Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.3.3 Mylan Laboratories Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Mylan Laboratories Main Business Overview
13.3.5 Mylan Laboratories Latest Developments
13.4 Takeda Pharmaceutical
13.4.1 Takeda Pharmaceutical Company Information
13.4.2 Takeda Pharmaceutical Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.4.3 Takeda Pharmaceutical Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Takeda Pharmaceutical Main Business Overview
13.4.5 Takeda Pharmaceutical Latest Developments
13.5 Emcure Pharmaceuticals
13.5.1 Emcure Pharmaceuticals Company Information
13.5.2 Emcure Pharmaceuticals Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.5.3 Emcure Pharmaceuticals Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Emcure Pharmaceuticals Main Business Overview
13.5.5 Emcure Pharmaceuticals Latest Developments
13.6 LUPIN PHARMS
13.6.1 LUPIN PHARMS Company Information
13.6.2 LUPIN PHARMS Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.6.3 LUPIN PHARMS Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 LUPIN PHARMS Main Business Overview
13.6.5 LUPIN PHARMS Latest Developments
13.7 Aurobindo Pharma
13.7.1 Aurobindo Pharma Company Information
13.7.2 Aurobindo Pharma Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.7.3 Aurobindo Pharma Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Aurobindo Pharma Main Business Overview
13.7.5 Aurobindo Pharma Latest Developments
13.8 Gilead Sciences
13.8.1 Gilead Sciences Company Information
13.8.2 Gilead Sciences Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.8.3 Gilead Sciences Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Gilead Sciences Main Business Overview
13.8.5 Gilead Sciences Latest Developments
13.9 Kainos Medicine
13.9.1 Kainos Medicine Company Information
13.9.2 Kainos Medicine Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.9.3 Kainos Medicine Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Kainos Medicine Main Business Overview
13.9.5 Kainos Medicine Latest Developments
13.10 Celltrion
13.10.1 Celltrion Company Information
13.10.2 Celltrion Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.10.3 Celltrion Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Celltrion Main Business Overview
13.10.5 Celltrion Latest Developments
13.11 Strides Pharma
13.11.1 Strides Pharma Company Information
13.11.2 Strides Pharma Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.11.3 Strides Pharma Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Strides Pharma Main Business Overview
13.11.5 Strides Pharma Latest Developments
13.12 Cipla
13.12.1 Cipla Company Information
13.12.2 Cipla Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.12.3 Cipla Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Cipla Main Business Overview
13.12.5 Cipla Latest Developments
13.13 Vibe Healthcare
13.13.1 Vibe Healthcare Company Information
13.13.2 Vibe Healthcare Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.13.3 Vibe Healthcare Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Vibe Healthcare Main Business Overview
13.13.5 Vibe Healthcare Latest Developments
13.14 Shionogi
13.14.1 Shionogi Company Information
13.14.2 Shionogi Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.14.3 Shionogi Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Shionogi Main Business Overview
13.14.5 Shionogi Latest Developments
13.15 ViiV Healthcare
13.15.1 ViiV Healthcare Company Information
13.15.2 ViiV Healthcare Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.15.3 ViiV Healthcare Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 ViiV Healthcare Main Business Overview
13.15.5 ViiV Healthcare Latest Developments
13.16 HETERO LABS
13.16.1 HETERO LABS Company Information
13.16.2 HETERO LABS Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.16.3 HETERO LABS Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 HETERO LABS Main Business Overview
13.16.5 HETERO LABS Latest Developments
13.17 Blanver Farmoquimica
13.17.1 Blanver Farmoquimica Company Information
13.17.2 Blanver Farmoquimica Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.17.3 Blanver Farmoquimica Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Blanver Farmoquimica Main Business Overview
13.17.5 Blanver Farmoquimica Latest Developments
13.18 Viriom
13.18.1 Viriom Company Information
13.18.2 Viriom Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.18.3 Viriom Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Viriom Main Business Overview
13.18.5 Viriom Latest Developments
13.19 Apotex
13.19.1 Apotex Company Information
13.19.2 Apotex Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.19.3 Apotex Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Apotex Main Business Overview
13.19.5 Apotex Latest Developments
13.20 DESANO
13.20.1 DESANO Company Information
13.20.2 DESANO Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.20.3 DESANO Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 DESANO Main Business Overview
13.20.5 DESANO Latest Developments
13.21 Hansoh Pharma
13.21.1 Hansoh Pharma Company Information
13.21.2 Hansoh Pharma Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.21.3 Hansoh Pharma Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Hansoh Pharma Main Business Overview
13.21.5 Hansoh Pharma Latest Developments
13.22 Genuine Biotech
13.22.1 Genuine Biotech Company Information
13.22.2 Genuine Biotech Nucleoside Reverse Transcriptase Inhibitors Product Portfolios and Specifications
13.22.3 Genuine Biotech Nucleoside Reverse Transcriptase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.22.4 Genuine Biotech Main Business Overview
13.22.5 Genuine Biotech Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
